FDA approves first therapy for symptomatic dermographism - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves first therapy for symptomatic dermographism

The oral BTK inhibitor produced a complete hive response in 29.3% of treated patients at week 12.

  • By

  • Teraya Smith

  • October 7, 2026

  • 2 min

Share

  • 1

    The FDA approved remibrutinib (Rhapsido) for adults with symptomatic dermographism inadequately controlled with H1 antihistamines.

  • 2

    Remibrutinib is the first FDA-approved treatment for symptomatic dermographism and is also approved for chronic spontaneous urticaria.

  • 3

    Approval was supported by the symptomatic dermographism cohort of the phase 3 RemIND trial, which compared remibrutinib with placebo.

  • 4

    At week 12, complete hive response occurred in 29.3% of remibrutinib-treated patients and 14.0% of placebo-treated patients; responses were reported as early as week 2.

  • 5

    Through week 24, common adverse events included nasopharyngitis, bleeding, headache, nausea, and abdominal pain; routine laboratory monitoring is not required.

Original Source(s)

FDA approves first therapy for symptomatic dermographism

  • by Teraya Smith

  • October 7, 2026

Related Content

AI Tool Finds More Long COVID Cases Than Codes

Nearly 90% of patients who met algorithmic criteria for postacute sequelae of SARS-CoV-2 infection had at least 1 chronic or potentially chronic condition requiring ongoing clinical management.

Daily Itch Duration Linked to Quality-of-Life Burden

Daily itch duration emerged as the strongest factor linking disease severity with quality of life, ahead of sleep disturbance, scratching frequency, and average itch intensity.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.